These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 28186869)

  • 1. Sedative-Hypnotic Drug Withdrawal Syndrome: Recognition And Treatment.
    Santos C; Olmedo RE
    Emerg Med Pract; 2017 Mar; 19(3):1-20. PubMed ID: 28186869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sedative-hypnotic drug withdrawal syndrome: recognition and treatment [digest].
    Santos C; Olmedo RE; Kim J
    Emerg Med Pract; 2017 Mar; 19(3 Suppl Points & Pearls):S1-S2. PubMed ID: 28745845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sedative-Hypnotic Agents That Impact Gamma-Aminobutyric Acid Receptors: Focus on Flunitrazepam, Gamma-Hydroxybutyric Acid, Phenibut, and Selank.
    Doyno CR; White CM
    J Clin Pharmacol; 2021 Aug; 61 Suppl 2():S114-S128. PubMed ID: 34396551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management and treatment of gamma butyrolactone withdrawal syndrome: a case report and review.
    Ghio L; Cervetti A; Respino M; Belvederi Murri M; Amore M
    J Psychiatr Pract; 2014 Jul; 20(4):294-300. PubMed ID: 25036586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GABA systems, benzodiazepines, and substance dependence.
    Malcolm RJ
    J Clin Psychiatry; 2003; 64 Suppl 3():36-40. PubMed ID: 12662132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical toxicology of γ-hydroxybutyrate, γ-butyrolactone and 1,4-butanediol.
    Schep LJ; Knudsen K; Slaughter RJ; Vale JA; Mégarbane B
    Clin Toxicol (Phila); 2012 Jul; 50(6):458-70. PubMed ID: 22746383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A role for valproate in the treatment of sedative-hypnotic withdrawal and for relapse prevention.
    Harris JT; Roache JD; Thornton JE
    Alcohol Alcohol; 2000; 35(4):319-23. PubMed ID: 10905994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sedative/hypnotic dependence: patient stabilization, tolerance testing, and withdrawal.
    Perry PJ; Alexander B
    Drug Intell Clin Pharm; 1986; 20(7-8):532-7. PubMed ID: 2874971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GHB pharmacology and toxicology: acute intoxication, concentrations in blood and urine in forensic cases and treatment of the withdrawal syndrome.
    Busardò FP; Jones AW
    Curr Neuropharmacol; 2015 Jan; 13(1):47-70. PubMed ID: 26074743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severe Carisoprodol Withdrawal After a 14-Year Addiction and Acute Overdose.
    Vo KT; Horng H; Smollin CG; Benowitz NL
    J Emerg Med; 2017 May; 52(5):680-683. PubMed ID: 27979642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treating acute withdrawal from alcohol and other drugs.
    Haack MR
    Nurs Clin North Am; 1998 Mar; 33(1):75-92. PubMed ID: 9478907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Abuse potential during use and withdrawal psychosis after treatment with the hypnotic zolpidem (Stilnoct)].
    Bruun TG
    Ugeskr Laeger; 1993 Aug; 155(35):2711-3. PubMed ID: 7786333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abrupt withdrawal from intrathecal baclofen: recognition and management of a potentially life-threatening syndrome.
    Coffey RJ; Edgar TS; Francisco GE; Graziani V; Meythaler JM; Ridgely PM; Sadiq SA; Turner MS
    Arch Phys Med Rehabil; 2002 Jun; 83(6):735-41. PubMed ID: 12048649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Withdrawal syndrome after abuse of GHB (Gamma-Hydroxybutyrate) and its physiological precursors - its relevance for child and adolescent psychiatrists].
    Zepf FD; Holtmann M; Duketis E; Maier J; Radeloff D; Schirman S; Wagner A; Poustka F; Wöckel L
    Z Kinder Jugendpsychiatr Psychother; 2009 Sep; 37(5):413-20. PubMed ID: 19739059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Managing benzodiazepine withdrawal during pregnancy: case-based guidelines.
    Gopalan P; Glance JB; Azzam PN
    Arch Womens Ment Health; 2014 Apr; 17(2):167-70. PubMed ID: 24271083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alcohol withdrawal syndrome: improving outcomes in the emergency department with aggressive management strategies.
    Yanta J; Swartzentruber G; Pizon A
    Emerg Med Pract; 2021 Mar; 23(Suppl 3):1-41. PubMed ID: 33729735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abuse liability of barbiturates and other sedative-hypnotics.
    Morgan WW
    Adv Alcohol Subst Abuse; 1990; 9(1-2):67-82. PubMed ID: 2198786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Gamma-hydroxy butyric acid: neurotransmitter, sedative and party drug].
    Meyer S; Kleinschmidt S; Gottschling S; Gortner L; Strittmatter M
    Wien Med Wochenschr; 2005 Jul; 155(13-14):315-22. PubMed ID: 16092038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pentobarbital for severe gamma-butyrolactone withdrawal.
    Sivilotti ML; Burns MJ; Aaron CK; Greenberg MJ
    Ann Emerg Med; 2001 Dec; 38(6):660-5. PubMed ID: 11719746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Psychiatric aspects of acute withdrawal from gamma-hydroxybutyrate (GHB) and its analogue gamma-butyrolactone (GBL): implications for psychiatry services in the general hospital.
    Choudhuri D; Cross S; Dargan PI; Wood DM; Ranjith G
    Int J Psychiatry Clin Pract; 2013 Jun; 17(2):154-6. PubMed ID: 23485126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.